Bracco and ACIST Medical Systems Announce U.S. FDA Clearance of ACIST Pro™ Diagnostic System: VIEW HERE

ACIST Diastolic Pressure Ratio (dPR)
Non-hyperemic index for coronary physiology

ACIST dPR is not approved in all markets

ACIST Diastolic Pressure Ratio (dPR)
Non-hyperemic index for coronary physiology

ACIST dPR is not approved in all markets

ACIST diastolic pressure ratio (dPR), using the ACIST RXi® Rapid Exchange System and Navvus® II MicroCatheter, provides a non-hyperemic alternative for physiological assessment of coronary disease.

Resources

ACIST RXi® EDUCATION
ACIST RXi® AND NAVVUS® II BROCHURE
IFUS AND USER MANUALS
DOWNLOAD NAVVUS® II BROCHURE
SERVICES AND SUPPORT
DOWNLOAD dPR BROCHURE

Reducing costs, time and patient discomfort

Non-hyperemic pressure ratios, such as dPR, may reduce patient discomfort*, cost** and procedural time.***

Reduced Patient Discomfort

Reduced Cost

Reduced Time

ACIST dPR algorithm

The dPR algorithm provides a non-hyperemic alternative for evaluating coronary artery stenosis by measuring a ratio of Pd to Pa at the peak-to-peak midpoint, averaged over five consecutive heartbeats, without relying on an ECG signal for the calculation.

ACIST dPR by the numbers

(compare to iFRcalc)1

0.89

dPR cutpoint

0.999

AUC

98.3%

Sensitivity

99.2%

Specificity

98.3%

PPV

99.2%

NPV

Analysis of the ACIST FFR Study1

Purpose

The data collected during the ACIST-FFR clinical study was retrospectively assessed by an independent, physiologic core laboratory to support ACIST’s dPR algorithm on the ACIST RXi system.

Methods

The dPR value was calculated by the application of ACIST’s fully automated off-line dPR software algorithm. iFRcalc was calculated off-line, by the same core lab, based on the original description of its derivation to determine a final value for iFR.2

Key points

  • ACIST dPR is highly correlated with iFRcalc
  • ACIST dPR provides similar diagnostic accuracy as iFRcalc

Results

Diagnostic accuracy of dPR (cutpoint of 0.89) referenced to iFRcalc (0.89) was 98.88%

References

* Reduced side effect profile when comparing resting approach (iFR, dPR, Pd/Pa) to FFR with adenosine induced hyperemia
** Cost savings based on the reduced cost of utilizing a resting approach compared to conventional FFR and respective cost of admInistration of hyperemic agent (adenosine)
*** When comparing resting index (iFR, dPR, Pd/Pa) to FFR with adenosine induced hyperemia
1. Data on file TR-07879
2. Sen S, Escaned J, Malik IS, et at. Development and validation of a new adenosine-independent index of stenosis severity from coronary wave-intensity analysis: results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) study. J Am Coll Cardbl. 2012:59(15)1392-1402. doi:10.1016/j.jacc.2011.11.003.

ACIST, ACIST FiXi and Nawus are trademarks of ACIST Medical Systems, Inc. ACIST Medical Systems, Inc., reserves the right to modify the specifications and features described herein, or discontinue manufacture of the product described at any time without prior notice or obligation. Please contact your authorized ACIST representative for the most current information.

© 2020 ACIST Medical Systems, Inc. Al Rights Reserved.

Interested in learning more?

Contact a rep to learn more about ACIST RXi and dPR.
find a rep
Skip to content